Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders

Malouf, Reem; Ashraf, Asma; Hadjinicolaou, Andreas V.; Dorée, Carolyn; Hopewell, Sally; Estcourt, Lise J

doi:10.1002/14651858.cd012342.pub2

Cited by 13 publications

(14 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Last, systematic reviews assessing the benefit of therapeutic vs prophylactic transfusion have been conducted concerning; congenital or acquired bone marrow failure (1 trial of 60 patients) 83 and following myelosuppressive chemotherapy or stem cell transplantation (6 conducted trials with 1195 patients) 84 …”

Section: Discussionmentioning

confidence: 99%

Thrombocytopenia in intensive care unit patients: A scoping review

Jonsson

Rygård

Hildebrandt

et al. 2020

Acta Anaesthesiol Scand

View full text Add to dashboard Cite

Background Thrombocytopenia is frequent in intensive care unit (ICU) patients and may be associated with adverse outcomes. We aimed to assess the incidence, risk factors, and outcomes associated with thrombocytopenia in adult ICU patients. Methods We conducted a scoping review in accordance with the Preferred Reporting Items for Systematic Review and Meta‐analyses extension for Scoping Reviews (PRISMA‐ScR) and the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. We included study reports on adult ICU patients with thrombocytopenia and assessed patient‐important outcomes, including mortality and health‐related quality‐of‐life. Results We included a total of 70 studies comprising a total of 215 098 patients; 57 were cohort studies. The incidence of thrombocytopenia varied from 8 to 56 per 100 admissions (very low quality of evidence). We identified several risk factors including age, sepsis, and higher disease severity (low quality of evidence). Thrombocytopenia was associated with bleeding, use of life support, length of stay in the ICU, and increased mortality (low/very low quality of evidence). Data on platelet transfusion before invasive procedures and transfusion thresholds were limited. No studies assessed the benefits and harms of thromboprophylaxis in ICU patients with thrombocytopenia. Conclusions Thrombocytopenia is common and associated with increased morbidity and mortality in adult ICU patients. Several risk factors for thrombocytopenia exists, but the evidence‐base on management strategies, including transfusion thresholds and thromboprophylaxis in ICU patients is very limited.

show abstract

Section: Discussionmentioning

confidence: 99%

Thrombocytopenia in intensive care unit patients: A scoping review

Jonsson

Rygård

Hildebrandt

et al. 2020

Acta Anaesthesiol Scand

View full text Add to dashboard Cite

show abstract

“…Thus, the power of miR-92a expression level serving as an independent prognostic indicator is essential and consistent under those subgroup factors. It should be clarified that with the absence of specific data in text for OS, the HRs and its corresponding confidence intervals of Jiang et al26, Ke et al20 and Lu et al25 were extracted by two independent authors (Lu Tang and Xiangcheng Qing) using the Kaplan-Meier Curves with Engauge Digitizer 9.8 and calculated in the spreadsheet calculator designed by Tierney JF et al42, whose accuracy had been proved by many researches48-50. The extracted results were always harmonious among the investigators but inconsistent with significance claimed in the original articles.…”

Section: Discussionmentioning

confidence: 99%

Investigation of MiR-92a as a Prognostic Indicator in Cancer Patients: a Meta-Analysis

et al. 2019

View full text Add to dashboard Cite

Background: MiR-92a has been discovered to be involved in the malignant behavior of various types of cancers. However, the particular clinical and prognostic roles of miR-92a in tumors still need to be identified more precisely. The current meta-analysis assessed the prognostic value of miR-92a in various carcinomas. Methods: Systematic literature searches of PubMed, PMC, Web of Science (WOS), Embase in English and Wanfang, SinoMed and the China National Knowledge Infrastructure (CNKI) in Chinese up to Jan 15 th 2019 were conducted for eligible studies. Twenty studies involving a total of 2573 patients were included in the analysis. Pooled hazard ratios (HR) for overall survival (OS) and disease-free survival (DFS), progression-free survival (PFS) and recurrence-free survival (RFS) were assessed using fixed-effects and random-effects models. Meta-regression and subgroup analyses were carried out to explore the source of heterogeneity. Odds ratio (OR) and 95%CIs were applied to evaluate the relationship between miR-92a expression levels and clinicopathological characteristics. Results: A significant association between miR-92a levels and OS (HR=2.18) was identified. The random pooling model also revealed significance of consistency (HR=2.14), indicating that the stability of the results. Subgroup analyses were performed and the corresponding significance was recognized in Chinese cancer patients (HR=2.35), studies of specimen derived from tissues (HR=2.43), non-hematological cancer (HR=2.35), osteosarcoma (HR=2.54), non-small cell lung cancer (HR=2.33), hepatocellular carcinoma (HR=2.40) and so on. There were significant relations observed of the expression level of miR-92a to tumor size (≥5 vs <5 cm) (OR=2.13), lymph node metastasis (present vs. absent) (OR=1.87), distant metastasis (present vs. absent) (OR=2.99) and so on. Conclusions: the over expression of miR-92a is associated with unfavorable prognosis of Chinese cancer patients. In addition, patients of elevated miR-92a expression level are likely to develop the cancers of more malignant behaviors.

show abstract

“…First of all, for lack of specific data in text for RFS, the relevant HRs and its confidence intervals of Fu et al [17] extracted by the Kaplan–Meier Curves with Engauge Digitizer 9.8 as well as the spreadsheet calculator designed by Tierney et al [33] did not support the significance claimed in the original article. The data were collected by two independent authors (Xiangyu Deng and Kaige Ma) from Fu et al [17] for several times using the methods described above whose accuracy had been proved by many researches [47–49]. The extracted data were always consistent but significantly different from the original articles.…”

Section: Discussionmentioning

confidence: 99%

MiR-19a as a prognostic indicator for cancer patients: a meta-analysis

Peng

Huang

et al. 2019

Bioscience Reports

View full text Add to dashboard Cite

MiR-19a was aberrantly expressed in various types of cancers and was observed to be potentially associated with the prognosis of cancer patients. The present analysis aims to elucidate its precise predictive value in various human malignancies. Online electronic searches of PubMed, Web of Science (WOS), Embase in English and VIP, Wanfang, SinoMed, and the China National Knowledge Infrastructure (CNKI) in Chinese up to September 8, 2018 were conducted. As a result, in overall analysis, a significant association was identified between miR-19a levels and OS (HRs = 2.31, CI: 1.11–4.83). The relation of miR-19a expression to OS was further recognized by fixed model within the studies of sample size less than 150 (HRs = 1.68, CI: 1.35–2.08), NOS scores greater than or equal to 8 (HRs = 1.53, CI: 1.13–2.06) or less than 8 (HRs = 1.89, CI: 1.58–2.27), specimen derived from tumor (HRs = 1.73, CI: 1.42–2.12) or blood (HRs = 1.87, CI: 1.46–2.40) and the patients of osteosarcoma (HRs = 7.17, CI: 5.04–10.21). Sensitivity analyses revealed no significant results. The association between miR-19a expression level and DFS was also found to be significant (HRs = 2.03, CI: 1.13–3.66). Correlations between miR-19a levels and clinicopathological features were examined and revealed that lymph node metastasis was significantly associated with miR-19a expression levels (OR = 0.565, CI: 0.346–0.921). Summarily, the over expression of miR-19a was an underlying risk of poor prognosis in many human malignancies, especially in osteosarcoma. Moreover, elevated miR-19a expression was linked to the potential of lymph node metastasis.

show abstract

Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders

Cited by 13 publications

References 77 publications

Thrombocytopenia in intensive care unit patients: A scoping review

Thrombocytopenia in intensive care unit patients: A scoping review

Investigation of MiR-92a as a Prognostic Indicator in Cancer Patients: a Meta-Analysis

MiR-19a as a prognostic indicator for cancer patients: a meta-analysis

Contact Info

Product

Resources

About